The European Commission has granted marketing authorization to Yuflyma, a biosimilar to Humira (adalimumab), making it available treat chronic inflammatory diseases.
Celltrion submits application for inhaled COVID-19 antibody treatment pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Celltrion submitted an IND application for a global Phase III clinical trial of inhaled antibody cocktail therapy with CT-P59 and CT-P63; the company expects to enrol 2,200 patients with mild-to-moderate
CT-P63 demonstrated a well- established safety profile in the global Phase I trial CT-P63 maintained strong neutralising ability against the Omicron variant (B.1.1.529) based on structural
Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529). The Phase I clinical trial is a randomised, double- blind and placebo- controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland.1 The study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug- related adverse events (AEs).